CliffBio
small molecule

MOXIFLOXACIN HYDROCHLORIDE

MOXIFLOXACIN HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameMOXIFLOXACIN HYDROCHLORIDE
Active ingredientMOXIFLOXACIN HYDROCHLORIDE
StrengthEQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2015
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.